Skip to main content

Our take —

This case-control study from Spain and Italy, available as a preprint and thus not yet peer reviewed, provides the first large-scale evidence of host genetic influence in severe COVID-19 disease, and identifies biological targets for further investigation. This analysis was only conducted in European populations, however these genetic variants do not vary widely between ancestries, and therefore should be similar across populations. Furthermore this study does not support a biological explanation for racial/ethnic disparities in COVID-19 morbidity and mortality both within the United States and globally. Finally, replication studies are needed with better control definitions and clinical characterizations to clarify the role of human genetics in COVID-19 severity, instead of overall frailty.

Study design

Case-Control

Study population and setting

A total of 1,610 patients with severe COVID-19 defined by hospitalization with respiratory failure were recruited from seven medical centers in Spain and Italy, and compared to 2,205 randomly selected blood donors. Population based-controls were significantly younger than cases; data were unavailable regarding pre-existing comorbidities or other relevant risk factors for COVID-19.

Summary of Main Findings

A genome-wide association study (GWAS) estimated the association between ~8 million single nucleotide polymorphisms (SNPs) across the human genome, adjusting for population substructure, age, and sex separately by country and then combined with a fixed-effects meta-analysis. Two regions were identified and met the threshold of genome-wide significance (P<10^-8): a region on chromosome 3 upstream of a solute carrier (SLC6A209) and a region on chromosome 9 overlapping the ABO blood group gene. Further analyses found a protective effect for blood group O, and an elevated risk for A positive individuals.

Study Strengths

By limiting cases to those hospitalized with documented COVID-19, the analysis is more likely to capture the host genetics underlying severe disease sequelae.

Limitations

This study uses population controls that are not documented to be exposed or tested for COVID-19, which could dilute the true effect size. Additionally, the combination of different age distributions in cases and controls (controls being significantly younger), and the lack of availability of additional clinical information such as comorbidities, makes the association inference unclear. The associated genetic regions may reflect a COVID-19-specific morbidity, an existing co-morbidity, or generally poorer health in an older population.

Value added

This study provides evidence that genetic variants may be partially responsible for differences in COVID-19 severity.

Our take —

This study adds valuable evidence that ACE inhibitors and angiostatin receptor blockers, two antihypertensive medications, are not associated with a heightened risk of COVID-19 or severe clinical illness.

Study design

Case-Control

Study population and setting

The study included as cases 6272 patients in Lombardy, Italy with laboratory-confirmed SARS-CoV-2 infection diagnosed between February 21 and March 11, 2020. 30,759 beneficiaries of the region’s public health system without diagnosed COVID-19 were used as controls, and were matched to cases by age, sex, and residency location.

Summary of Main Findings

While the use of antihypertensive medications, including ACE inhibitors and angiotensin receptor blockers (ARBs), was more common among patients with COVID-19 than among controls, this association disappeared after accounting for relevant clinical factors such as pre-existing diagnoses. COVID-19 diagnosis was not associated with either ACE inhibitor use (Odds ratio [OR]=0.96, 95% CI: 0.87,1.07) or ARB use (OR=0.95, 95% CI: 0.86,1.05). Restricting cases to those with severe clinical disease produced similar results for both ACE inhibitors (OR=0.91, 95%CI: 0.69,1.21) and ARBs (OR=0.83, 95% CI: 0.63,1.10).

Study Strengths

The study used a large sample size across many healthcare settings. Sensitivity analyses were well-conceived, accounting for uncertainty in the ascertainment of medication use.

Limitations

Given that the fundamental question is whether certain antihypertensive medications modulate the risk of severe disease, it would have been more appropriate to limit the primary analysis to those with a hypertension diagnosis. Similarly, it would likely have been more appropriate to limit the analysis of predictors of severe disease to those with a COVID-19 diagnosis. Doing so mitigates the risk of confounding by hospital presentation, health status, and more.

Value added

This study adds valuable evidence that ACE inhibitors and angiostatin receptor blockers are not associated with a heightened risk of COVID-19 or severe clinical illness.

Our take —

Markers of liver dysfunction in COVID-19 patients were elevated slightly, but not to a clinically significant degree. Liver dysfunction was not more pronounced than in a control group with community-acquired pneumonia, and did not predict COVID-19 severity. The small sample size and single location limit generalizability.

Study design

Case-Control

Study population and setting

Cases were comprised of all 115 health care workers and family members (>14 years old without hepatitis B infection) with confirmed SARS-CoV-2 infection who were admitted to Zhongnan Hospital of Wuhan University, Wuhan, China, from 1/18/20 to 2/22/20. Controls were 119 patients with community-acquired pneumonia from the same hospital.

Summary of Main Findings

Serum markers of liver dysfunction and inflammation were not significantly elevated in COVID-19 patients relative to community-acquired pneumonia patients. Only the neutrophil-to-lymphocyte ratio was a predictor of COVID-19 severity.

Study Strengths

Patients were tested for a wide array of liver function indices. The presence of a control group improves the validity of the analysis.

Limitations

The sample size is small and comes from a single hospital. There were few (n=31) severe cases of COVID-19. The comparison groups may differ by much more than just disease etiology – healthcare workers and their families represent a different population than the broader patient population. Because the sensitivity of the SAR-CoV-2 diagnostic testing is, as yet, unclear, COVID-19 patients may have been incorrectly classified as having non-COVID pneumonia, thus biasing the results.

Value added

This is one of the first studies to focus specifically on liver dysfunction as a manifestation of COVID-19.

Our take —

This study compares the blood groups of those with diagnosed COVID-19 and those from a historical control cohort. While the results indicate a signal between blood group O and a decreased risk of disease, this should be interpreted with caution given that we cannot rule out other major differences in this study between cases with COVID-19 and historical controls (e.g. age distribution).

Study design

Case-Control

Study population and setting

This was an unmatched case-control study, in which ABO-typed blood samples were collected from infected hospital cases, and ABO blood group distribution was captured from recent surveys of “normal people” to serve as comparison controls. Cases were included from three hospitals in Wuhan, Hubei province and Shenzhen, Guangdong province, China.  No specific time period was provided for when cases were infected or selected, and information was not provided on controls. There were a total of 1775 patients infected with SARS-CoV-2 (COVID-19 cases), including 206 deaths, from the Jinyintan Hospital in Wuhan. An additional 113 COVID-19 cases were included from Renmin Hospital of Wuhan University, and 285 COVID-19 cases from Shenzhen Third People’s Hospital. There were a total of 3694 controls from Wuhan City and 23386 controls from Shenzhen City.

Summary of Main Findings

Blood group A was associated with an increased risk for COVID-19, whereas blood group O was associated with a decreased risk, suggesting that the ABO blood type is a biomarker for differential susceptibility to COVID-19.

Study Strengths

There are few studies that have examined differential susceptibility to SARS-CoV-2 infection; ultimately this study assesses susceptibility to COVID-19 (disease status, not infection), but generates future hypotheses for testing around blood type and infection, as well as further analyses of progression to disease.  While multivariable analyses were not possible and therefore the role of chronic medical conditions is still unclear, this study made use of existing hospital data and surveys in order to do a rapid and methodologically replicable examination of a potential biomarker for COVID-19 susceptibility.

Limitations

The control group appears to have been sampled years before the study, is from a different source population and appears to have differences in at least age composition from the target population. Further, because controls are historical, we do not know if they ultimately were infected during the time period of this study.

Value added

This is one of the first studies of risk factors for COVID-19 susceptibility. This has potential implications for future prevention efforts (e.g. biomarker for who might need extra protection or who may need to take extra precautions against infection), however underlying methodological issues suggest caution in terms of interpretation. Importantly, a biological mechanism was hypothesized, though it requires further assessment. Ongoing and future serological studies with case reporting ascertainment may also consider assessment of blood type.